{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:43Z","timestamp":1794893623482,"version":"4.9.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Succinate dehydrogenase (SDH), a critical enzyme in the citric acid cycle and respiratory electron transport chain, consists of 4 subunits: SDHA, SDHB, SDHC, and SDHD. Deficiency of a single subunit leads to the loss of SDH activity which is implicated in the development of a subset of gastrointestinal stromal tumors (GISTs): SDH-deficient GISTs. These GISTs arise almost exclusively in the stomach, have a female predilection, and primarily affect children and young adults. Their characteristic morphologic features include multinodular architecture, lymphovascular invasion, and lymph node metastasis. At the molecular level, these tumors lack\n                    <jats:italic toggle=\"yes\">KIT<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">PDGFRA, BRAF<\/jats:italic>\n                    , or\n                    <jats:italic toggle=\"yes\">NF1<\/jats:italic>\n                    mutations, which are alternative oncogenic drivers typically observed in GIST. Recently, a sarcoma DNA methylation classifier was developed and was shown to be a valuable diagnostic tool. This study evaluated the DNA methylation classifier results for 30 SDH-deficient GISTs and discovered that methylation profiles clustered in a unique region separate from GISTs and leiomyosarcomas. Moreover,\n                    <jats:italic toggle=\"yes\">MGMT<\/jats:italic>\n                    promoter methylation, a predictive biomarker of tumor cell sensitivity to alkylating agent chemotherapy, was identified in 6 primary and 5 metastatic tumors. In addition, 3 primary and 4 metastatic tumors showed gain\/low-level amplification of\n                    <jats:italic toggle=\"yes\">MDM4<\/jats:italic>\n                    , which pathologically activates MDM4-p53 axis, a target of inhibitors. In summary, these findings expand the sarcoma DNA methylation classifier to include SDH-deficient GIST as a new sarcoma DNA methylation entity and identified 2 predictive biomarkers for targeted therapy: methylation of\n                    <jats:italic toggle=\"yes\">MGMT<\/jats:italic>\n                    promoter and gain\/low-level amplification of\n                    <jats:italic toggle=\"yes\">MDM4<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002444","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T12:00:54Z","timestamp":1752062454000},"page":"1105-1113","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["DNA Methylation Profiling Separates SDH-Deficient GISTs From KIT-PDGFRA-Driven GISTs and Identifies Predictive Biomarkers for Targeted Therapy"],"prefix":"10.1097","volume":"49","author":[{"given":"Ma\u0142gorzata","family":"Ch\u0142opek","sequence":"first","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Lasota","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkar","family":"Singh","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blakely","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glod","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Ylaya","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kaczorowski","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"},{"name":"Department of Clinical and Experimental Pathology, Wroc\u0142aw Medical University, Wroc\u0142aw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lie","family":"Klub\u00ed\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen"},{"name":"Bioptick\u00e1 Laborato\u0159 Ltd, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szumera-Cie\u0107kiewicz","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Michal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen"},{"name":"Bioptick\u00e1 Laborato\u0159 Ltd, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zied","family":"Abdullaev","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Aldape","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"R1-20251022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"R2-20251022","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41467-020-20603-4","article-title":"Sarcoma classification by DNA methylation profiling","volume":"12","author":"Koelsche","year":"2021","journal-title":"Nat Commun"},{"key":"R3-20251022","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cjp2.215","article-title":"DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the \u201cDKFZ Sarcoma Classifier\u201d","volume":"7","author":"Lyskjaer","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"R4-20251022","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13148-022-01365-w","article-title":"Sarcoma classification by DNA methylation profiling in clinical everyday life: the Charit\u00e9 experience","volume":"14","author":"Roohani","year":"2022","journal-title":"Clin Epigenetics"},{"key":"R5-20251022","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PAS.0000000000002138","article-title":"Assessment of the utility of the sarcoma DNA methylation classifier in surgical pathology","volume":"48","author":"Miettinen","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R6-20251022","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.mito.2010.03.001","article-title":"Succinate dehydrogenase\u2014assembly, regulation and role in human disease","volume":"10","author":"Rutter","year":"2010","journal-title":"Mitochondrion"},{"key":"R7-20251022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PAT.0b013e3283539932","article-title":"Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia","volume":"44","author":"Gill","year":"2012","journal-title":"Pathology"},{"key":"R8-20251022","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","article-title":"SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma","volume":"325","author":"Hao","year":"2009","journal-title":"Science"},{"key":"R9-20251022","doi-asserted-by":"crossref","first-page":"680609","DOI":"10.3389\/fendo.2021.680609","article-title":"Carney triad, Carney-Stratakis syndrome, 3PAS and other tumors due to SDH deficiency","volume":"12","author":"Pitsava","year":"2021","journal-title":"Front Endocrinol"},{"key":"R10-20251022","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.biocel.2014.05.033","article-title":"Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs)\u2014a review","volume":"53","author":"Miettinen","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"R11-20251022","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/PAS.0000000000000685","article-title":"Conventional risk stratification fails to predict progression of succinate dehydrogenase-deficient gastrointestinal stromal tumors: a clinicopathologic study of 76 cases","volume":"40","author":"Mason","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R12-20251022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/PAS.0000000000001377","article-title":"Colonic adenocarcinomas harboring NTRK fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature","volume":"44","author":"Lasota","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R13-20251022","first-page":"e123","article-title":"SeSAMe: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions","volume":"46","author":"Zhou","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R14-20251022","doi-asserted-by":"crossref","first-page":"115222","DOI":"10.1016\/j.eswa.2021.115222","article-title":"Nested cross-validation when selecting classifiers is overzealous for most practical applications","volume":"182","author":"Wainer","year":"2021","journal-title":"Expert Syst Appl"},{"key":"R15-20251022","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41596-019-0251-6","article-title":"Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data","volume":"15","author":"Maros","year":"2020","journal-title":"Nat Protoc"},{"key":"R16-20251022","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jmoldx.2015.11.009","article-title":"Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors","volume":"18","author":"Bady","year":"2016","journal-title":"J Mol Diagn"},{"key":"R17-20251022","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41379-021-00874-y","article-title":"Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature","volume":"34","author":"Koelsche","year":"2021","journal-title":"Mod Pathol"},{"key":"R18-20251022","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","article-title":"Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor","volume":"3","author":"Killian","year":"2013","journal-title":"Cancer Discov"},{"key":"R19-20251022","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1530\/ERC-14-0254","article-title":"Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad","volume":"21","author":"Haller","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"R20-20251022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy","volume":"9","author":"Yu","year":"2020","journal-title":"Front Oncol"},{"key":"R21-20251022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT promoter methylation in malignant gliomas: ready for personalized medicine?","volume":"6","author":"Weller","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R22-20251022","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","article-title":"Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations","volume":"108","author":"Janeway","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"R23-20251022","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","article-title":"Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors","volume":"38","author":"Neppala","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"R24-20251022","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"R25-20251022","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/cncr.11875","article-title":"A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas","volume":"98","author":"Trent","year":"2003","journal-title":"Cancer"},{"key":"R26-20251022","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/cncr.21384","article-title":"A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas","volume":"104","author":"Garcia del Muro","year":"2005","journal-title":"Cancer"},{"key":"R27-20251022","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-21-2092","article-title":"Establishment of patient-derived succinate dehydrogenase-deficient gastrointestinal stromal tumor models for predicting therapeutic response","volume":"28","author":"Yebra","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R28-20251022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/jcp-2022-208462","article-title":"Preferential MGMT hypermethylation in SDH-deficient wild-type GIST","volume":"77","author":"Giger","year":"2023","journal-title":"J Clin Pathol"},{"key":"R29-20251022","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13148-018-0594-9","article-title":"Preferential MGMT methylation could predispose a subset of KIT\/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents","volume":"11","author":"Ricci","year":"2019","journal-title":"Clin Epigenetics"},{"key":"R30-20251022","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.prp.2017.10.007","article-title":"Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas","volume":"213","author":"Wang","year":"2017","journal-title":"Pathol Res Pract"},{"key":"R31-20251022","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/s41467-018-05373-4","article-title":"A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun"},{"key":"R32-20251022","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41467-020-17717-0","article-title":"MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas","volume":"11","author":"Oldrini","year":"2020","journal-title":"Nat Commun"},{"key":"R33-20251022","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ygeno.2011.07.007","article-title":"High density DNA methylation array with single CpG site resolution","volume":"98","author":"Bibikova","year":"2011","journal-title":"Genomics"},{"key":"R34-20251022","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.biocel.2007.03.022","article-title":"MDM2 and MDM4: p53 regulators as targets in anticancer therapy","volume":"39","author":"Toledo","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"R35-20251022","first-page":"61","article-title":"MDMX in cancer: a partner of p53 and a p53-independent effector","volume":"18","author":"Lin","year":"2024","journal-title":"Biologics"},{"key":"R36-20251022","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41598-021-82542-4","article-title":"MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma","volume":"11","author":"Woodfield","year":"2021","journal-title":"Sci Rep"},{"key":"R37-20251022","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3389\/fonc.2020.01389","article-title":"Targeting MDMX for cancer therapy: rationale, strategies, and challenges","volume":"10","author":"Yu","year":"2020","journal-title":"Front Oncol"},{"key":"R38-20251022","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejmech.2019.05.018","article-title":"The past, present and future of potential small-molecule drugs targeting p53-MDM2\/MDMX for cancer therapy","volume":"176","author":"Liu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"R39-20251022","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/biomedicines11071967","article-title":"The novel MDM4 inhibitor CEP-1347 activates the p53 pathway and blocks malignant meningioma growth in vitro and in vivo","volume":"11","author":"Mitobe","year":"2023","journal-title":"Biomedicines"},{"key":"R40-20251022","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/cancers16010118","article-title":"CEP-1347 dually targets MDM4 and PKC to activate p53 and inhibit the growth of uveal melanoma cells","volume":"16","author":"Togashi","year":"2023","journal-title":"Cancers"},{"key":"R41-20251022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ijc.21206","article-title":"Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis","volume":"117","author":"Bartel","year":"2005","journal-title":"Int J Cancer"},{"key":"R42-20251022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/gcc.23130","article-title":"MDM4 amplification in atypical lipomatous tumors\/well-differentiated liposarcoma: private event or alternative oncogenic mechanism?","volume":"62","author":"Gruel","year":"2023","journal-title":"Genes Chromosomes Cancer"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T13:00:24Z","timestamp":1761138024000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002444","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]}}}